Back to Network
11
Shared Docs
11
Same-Page
11 / 11
Mentions
Document Mentions (11 shared documents)
2 mentions1 same-page
Page ?Same page
ts on fixed income, mandatory converts Jeffrey. Rich mentioned you're interested in potentially buying
pital to drive shareholder return. Next catalyst will be 2Q earnings/2/116 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We continue to like TEVA's positioning In generic pharma where s
2 mentions1 same-page
Page ?Same page
ts on fixed income, mandatory converts Jeffrey, Rich mentioned you're interested in potentially buying
capital to drive shareholder return. Next catalyst will be 2Q eamings/2H16 Outlook on 8/8. AGN Is on our firm's US-1 list of best Investment Ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTCs approval of AGN generics deal. We continue to like TEVA's positioning In generic pharma where sc
2 mentions1 same-page
Page ?Same page
gc015.jpg: image016.jpg: image017.jpg Jeffrey, Rich mentioned you're interested in potentially buying
pital to drive shareholder return. Next catalyst will be 2Q earnings/V.116 Outlook on 8/8. AGN Is on our firm's US-1 list of best investment Ideas. Teva Pharma (TWA) - BAML reiterating BUY on TEVA after the FTCs approval of AGN generics deal. We continue to like TEVA's positioning in generic pharma where sca
Sponsored
2 mentions1 same-page
Page ?Same page
fixed income, mandatory converts Jeffrey, =/u> Rich mentioned you're=interested in potentially buying
apital to drive shareholder return. Next catalyst will be 2Q earni=gs/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML=reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We co=tinue to like TEVA's positioning in generic pharma where
2 mentions1 same-page
Page ?Same page
ts on fixed income, mandatory converts Jeffre=, Rich m=ntioned you're interested in potentially buying
l to drive shareholder return. N=xt catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm :=17;s US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval=of AGN generics deal. We continue to like TEVA's positioning in generic=pharma where
2 mentions1 same-page
Page ?Same page
fixed income, mandatory converts Jeffrey, =/u> Rich mentioned you're=interested in potentially buying
apital to drive shareholder return. Next catalyst will be 2Q earni=gs/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML=reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We co=tinue to like TEVA's positioning in generic pharma where
Sponsored
2 mentions1 same-page
Page ?Same page
ts on fixed income, mandatory converts Jeffrey, Rich mentioned you're interested in potentially buying
pital to drive shareholder return. Next catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We continue to like TEVA's positioning in generic pharma where
2 mentions1 same-page
Page ?Same page
ts on fixed income, mandatory converts Jeffrey, Rich mentioned you're interested in potentially buying
apital to drive shareholder return. Next catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We continue to like TEVA's positioning in generic pharma where
2 mentions1 same-page
Page ?Same page
ts on fixed income, mandatory converts Jeffrey, Rich mentioned you're interested in potentially buying
apital to drive shareholder return. Next catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We continue to like TEVA's positioning in generic pharma where
Sponsored
2 mentions1 same-page
Page ?Same page
fixed income, mandatory converts Jeffrey, =/u> Rich mentioned you're=interested in potentially buying
apital to drive shareholder return. Next catalyst will be 2Q earni=gs/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML=reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We co=tinue to like TEVA's positioning in generic pharma where
Sponsored
Mutual Connections (35)
Entities connected to both Marc Rich and Teva Pharma
Jeffrey Epstein
PERSON22,722 w/ Marc·11 w/ Teva
Richard Kahn
PERSON19,040 w/ Marc·11 w/ Teva
NEW YORK NY
LOCATION966 w/ Marc·2 w/ Teva
Bloomberg L.P.
ORGANIZATION320 w/ Marc·11 w/ Teva
AM
Amanda
PERSON224 w/ Marc·8 w/ Teva
Bank of America
ORGANIZATION66 w/ Marc·4 w/ Teva
Pierce, Fenner & Smith Incorporated
ORGANIZATION48 w/ Marc·5 w/ Teva
Paul Volcker
PERSON41 w/ Marc·11 w/ Teva
AE
Amanda Ens
PERSON44 w/ Marc·7 w/ Teva
Frontier Communications
ORGANIZATION29 w/ Marc·11 w/ Teva
HM
Hans Mikkelsen
PERSON12 w/ Marc·11 w/ Teva
Chart One
ORGANIZATION11 w/ Marc·11 w/ Teva
Spec Pharma
ORGANIZATION12 w/ Marc·10 w/ Teva
US Treasury ETF
ORGANIZATION11 w/ Marc·11 w/ Teva
S&P500 ETF
ORGANIZATION11 w/ Marc·11 w/ Teva
Investment Grade Supply
ORGANIZATION11 w/ Marc·11 w/ Teva
Investment Grade ETF
ORGANIZATION11 w/ Marc·11 w/ Teva
Frontier Comm
ORGANIZATION10 w/ Marc·10 w/ Teva
Outlook
ORGANIZATION13 w/ Marc·6 w/ Teva
Allergan
LOCATION9 w/ Marc·9 w/ Teva